News Novo taps Anthropic's Claude AI for drug discovery Novo adds Anthropic AI models and Claude Science to its drug discovery toolkit in a bid to become "the world's most AI-driven healthcare company."
News Claude Science outperforms experts in protein binder task Using Claude Science, Claude agents designed high-affinity protein binders for a range of targets, outperforming human experts in some cases.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.